hidradenitis suppurativa
Information
- Disease name
- hidradenitis suppurativa
- Disease ID
- DOID:2280
- Description
- "A hidradenitis that is characterized by chronic inflammation of the apocrine sweat glands, has_symptom painful nodules, abscesses, sinus tract formation, scarring, erythema, pruritis, and pain, and has_material_basis_in chronic inflammation of the apocrine sweat glands leading to recurrent folliculitis and an accompanying immune response that worsens inflammation." [url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402905/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05057429 | Active, not recruiting | N/A | A Bioelectric Dressing for Post De-Roofing Treatment of HS | October 11, 2021 | August 1, 2024 |
| NCT05849922 | Active, not recruiting | Phase 2 | A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa | June 6, 2023 | January 8, 2025 |
| NCT05905783 | Active, not recruiting | Phase 3 | Hidradenitis Suppurativa Study of Izokibep | June 22, 2023 | May 2025 |
| NCT04901195 | Active, not recruiting | Phase 3 | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | May 27, 2021 | July 28, 2026 |
| NCT04200690 | Active, not recruiting | N/A | Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases | January 14, 2020 | January 31, 2024 |
| NCT04179175 | Active, not recruiting | Phase 3 | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa | March 18, 2020 | July 15, 2026 |
| NCT03572738 | Active, not recruiting | Hidradenitis Suppurativa Mail Survey | May 14, 2018 | November 2024 | |
| NCT00918255 | Completed | Phase 2 | Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa | April 2009 | November 2010 |
| NCT00949546 | Completed | Treatment of Hidradenitis Suppurativa Using Etanercept | April 2005 | January 2008 | |
| NCT01063270 | Completed | N/A | Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa | February 2010 | December 2013 |
| NCT01352078 | Completed | Wound Etiology and Healing Study | May 2011 | January 2022 | |
| NCT01516749 | Completed | Phase 2 | Anakinra as a Treatment for Hydradenitis Suppurativa | October 2012 | July 2013 |
| NCT01558375 | Completed | Phase 2 | Anakinra in Hidradenitis Suppurativa | March 2012 | February 2014 |
| NCT01635764 | Completed | Phase 3 | Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa | April 2012 | August 2016 |
| NCT01704534 | Completed | Phase 2 | A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa | May 2012 | April 2014 |
| NCT01818167 | Completed | N/A | An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa. | January 5, 2013 | January 21, 2015 |
| NCT02163746 | Completed | N/A | Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing | January 14, 2015 | June 7, 2016 |
| NCT02593604 | Completed | Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa | March 15, 2015 | April 15, 2017 | |
| NCT02643654 | Completed | Phase 2 | MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB | December 2015 | February 2017 |
| NCT02695212 | Completed | Phase 2 | Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa | July 2016 | August 2017 |
| NCT02739828 | Completed | Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients | April 7, 2016 | March 28, 2018 | |
| NCT02781818 | Completed | N/A | A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. | June 2016 | July 2017 |
| NCT02786576 | Completed | Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting | July 5, 2016 | January 7, 2019 | |
| NCT02805595 | Completed | Phase 2 | Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa | August 2016 | November 2022 |
| NCT02833909 | Completed | N/A | Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients | March 2015 | March 2016 |
| NCT02904902 | Completed | Phase 3 | Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa | September 6, 2016 | May 30, 2019 |
| NCT03001622 | Completed | Phase 2 | Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa | December 2016 | July 2017 |
| NCT03049267 | Completed | Phase 2 | Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis | February 2, 2017 | June 28, 2018 |
| NCT03054155 | Completed | N/A | Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser | May 11, 2017 | October 31, 2022 |
| NCT03099980 | Completed | Early Phase 1 | Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa | July 11, 2016 | January 2019 |
| NCT03103074 | Completed | N/A | Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa | June 1, 2017 | September 23, 2018 |
| NCT03288337 | Completed | Impact of Hidradenitis Suppurativa on Quality of Life Functions | April 2015 | September 6, 2022 | |
| NCT00134134 | Completed | Phase 1 | Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa | February 2005 | August 2006 |
| NCT00329823 | Completed | Phase 2 | Etanercept in Hidradenitis Suppurativa | September 2005 | May 2006 |
| NCT00395187 | Completed | N/A | A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa | October 2006 | September 2007 |
| NCT00494351 | Completed | N/A | Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa | June 2007 | July 2009 |
| NCT00795574 | Completed | Phase 2 | Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa | June 2005 | August 2008 |
| NCT00827996 | Completed | Phase 2 | To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa | February 2007 | August 2008 |
| NCT03248531 | Completed | Phase 2 | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. | September 22, 2017 | February 21, 2019 |
| NCT03275870 | Completed | Phase 1/Phase 2 | Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa | September 28, 2017 | June 30, 2019 |
| NCT00107991 | Completed | Phase 2 | Etanercept for Treatment of Hidradenitis | April 2005 | November 2008 |
| NCT03289585 | Completed | A National Registry For Patients With Hidradenitis Suppurativa | August 2015 | September 6, 2022 | |
| NCT03512275 | Completed | Phase 2 | A Study of Bermekimab in Patients With Hidradenitis Suppurativa | June 20, 2018 | January 14, 2019 |
| NCT03569371 | Completed | Phase 2 | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | July 17, 2018 | April 22, 2019 |
| NCT03607487 | Completed | Phase 2 | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | October 15, 2018 | August 13, 2019 |
| NCT03628924 | Completed | Phase 2 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | September 4, 2018 | May 22, 2020 |
| NCT03668925 | Completed | N/A | Association Between Hidradenitis Suppurativa and Spondyloarthritis | May 1, 2013 | September 1, 2015 |
| NCT03683238 | Completed | Nutritional Status and Hidradenitis Suppurativa (Acne Inversa) | May 2015 | May 2018 | |
| NCT03713619 | Completed | Phase 3 | This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). | January 31, 2019 | July 26, 2022 |
| NCT03713632 | Completed | Phase 3 | Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) | February 25, 2019 | July 19, 2022 |
| NCT03852472 | Completed | Phase 2 | Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) | December 21, 2018 | March 9, 2021 |
| NCT03926169 | Completed | Phase 2 | A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | June 3, 2019 | August 2, 2021 |
| NCT03960268 | Completed | Early Phase 1 | Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab | May 28, 2019 | June 1, 2020 |
| NCT03972280 | Completed | Phase 1 | Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis | July 4, 2019 | October 4, 2022 |
| NCT04018599 | Completed | Phase 1 | Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS | July 15, 2019 | March 17, 2020 |
| NCT04019041 | Completed | Phase 2 | A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa | September 16, 2019 | November 17, 2020 |
| NCT04061395 | Completed | Phase 2 | Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. | October 1, 2019 | April 1, 2022 |
| NCT04194541 | Completed | N/A | Wound Dressings for Hidradenitis Suppurativa | January 28, 2020 | March 8, 2021 |
| NCT04242446 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | February 19, 2020 | February 19, 2023 |
| NCT04242498 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | March 2, 2020 | September 28, 2022 |
| NCT04251663 | Completed | Complement C5a Receptors in Hidradenitis Suppurativa | July 18, 2019 | July 29, 2022 | |
| NCT04440410 | Completed | Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis | May 28, 2020 | March 24, 2021 | |
| NCT04449354 | Completed | N/A | HidraWear AX HS Study | October 30, 2019 | October 3, 2020 |
| NCT04476043 | Completed | Phase 2 | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | August 25, 2020 | August 16, 2023 |
| NCT04493502 | Completed | Phase 2 | A Study of LY3041658 in Adults With Hidradenitis Suppurativa | August 26, 2020 | October 13, 2022 |
| NCT04600375 | Completed | N/A | Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa | October 20, 2020 | December 7, 2020 |
| NCT04648631 | Completed | N/A | Hidradenitis Suppurativa (HS) Tunneling Wounds | February 26, 2021 | July 28, 2022 |
| NCT04649502 | Completed | Phase 3 | Metformin for the Treatment of Hidradenitis Suppurativa (HS) | January 25, 2021 | August 23, 2023 |
| NCT04756336 | Completed | Phase 1/Phase 2 | LTX-109 as Treatment for Hidradenitis Suppurativa | March 5, 2021 | July 1, 2021 |
| NCT04762277 | Completed | Phase 2 | A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa | April 6, 2021 | April 21, 2022 |
| NCT04772885 | Completed | Phase 1 | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) | February 23, 2021 | October 20, 2022 |
| NCT04856930 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa | July 7, 2021 | December 14, 2022 |
| NCT04876391 | Completed | Phase 2 | A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial | July 27, 2021 | April 26, 2024 |
| NCT04979520 | Completed | Early Phase 1 | Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa | August 5, 2021 | July 25, 2022 |
| NCT04989517 | Completed | Phase 1 | Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa | November 23, 2021 | March 15, 2023 |
| NCT05040698 | Completed | Phase 2 | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa | October 1, 2021 | January 27, 2023 |
| NCT05093855 | Completed | Phase 2 | Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | August 18, 2021 | August 22, 2023 |
| NCT05103423 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | June 24, 2021 | July 7, 2023 |
| NCT05125458 | Completed | Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Diseases. | April 1, 2021 | November 30, 2022 | |
| NCT05194969 | Completed | N/A | Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery | April 25, 2022 | October 30, 2023 |
| NCT05216224 | Completed | Phase 2 | ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | December 29, 2021 | January 24, 2023 |
| NCT05286567 | Completed | Phase 1 | A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. | September 1, 2021 | August 29, 2022 |
| NCT05322473 | Completed | Phase 2 | Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa | April 25, 2022 | August 30, 2023 |
| NCT05355805 | Completed | Phase 2 | Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep | May 5, 2022 | February 21, 2024 |
| NCT05635838 | Completed | Phase 2 | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | December 7, 2022 | March 14, 2024 |
| NCT05663268 | Completed | Early Phase 1 | Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa | October 1, 2022 | September 30, 2023 |
| NCT05927948 | Completed | N/A | Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa | November 4, 2019 | December 1, 2021 |
| NCT05084417 | Enrolling by invitation | A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions | June 9, 2023 | January 15, 2026 | |
| NCT05208099 | Not yet recruiting | Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy | January 1, 2024 | June 30, 2026 | |
| NCT06237465 | Not yet recruiting | Phase 4 | Botulinum Toxin-A for Hidradenitis Suppurativa | April 2024 | January 2025 |
| NCT05484674 | Not yet recruiting | N/A | Control of Hidradenitis Suppurativa of the Underarms After Combination Deroofing and Laser | August 6, 2022 | December 6, 2023 |
| NCT06444087 | Not yet recruiting | Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation | June 30, 2024 | March 30, 2027 | |
| NCT05821478 | Not yet recruiting | Phase 3 | Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients | April 15, 2024 | September 15, 2026 |
| NCT05580029 | Not yet recruiting | Early Phase 1 | Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions | November 1, 2022 | March 1, 2023 |
| NCT04388163 | Not yet recruiting | Phase 2 | Gentian Violet Treatment for Hidradenitis Suppurativa | July 2024 | December 2024 |
| NCT06301256 | Not yet recruiting | N/A | Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa | March 11, 2024 | March 11, 2025 |
| NCT06370052 | Not yet recruiting | Pathophysiological Basis of Hidradenitis Suppurativa | May 1, 2024 | December 31, 2026 | |
| NCT06201858 | Not yet recruiting | A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa | January 2025 | January 2027 | |
| NCT06324695 | Not yet recruiting | N/A | Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases | March 2024 | March 2025 |
| NCT06082323 | Not yet recruiting | Phase 1 | A Single and Multiple Ascending Dose Trial of LT-002-158 in Healthy Adult Volunteers | June 13, 2024 | March 10, 2025 |
| NCT06326476 | Not yet recruiting | Early Phase 1 | A Study to Demonstrate the Safety and Efficacy of Siplizumab in the Treatment of Hidradenitis Suppurativa | January 2025 | December 31, 2025 |
| NCT05470322 | Not yet recruiting | N/A | Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients | July 2024 | December 2025 |
| NCT05994976 | Recruiting | Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers | October 17, 2023 | August 2028 | |
| NCT05066113 | Recruiting | N/A | Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin | August 15, 2017 | August 2027 |
| NCT06324552 | Recruiting | Defects of Keratinocytes Function in Dermatologic Patients | October 12, 2020 | August 31, 2024 | |
| NCT05139602 | Recruiting | Phase 2 | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy | December 28, 2021 | January 24, 2026 |
| NCT06361836 | Recruiting | Phase 1 | Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa | May 2024 | June 2026 |
| NCT05243966 | Recruiting | Myriad™ Augmented Soft Tissue Reconstruction Registry | January 10, 2022 | January 2029 | |
| NCT04414514 | Recruiting | Phase 2 | Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment | October 13, 2022 | January 2025 |
| NCT06368388 | Recruiting | Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force | June 1, 2021 | June 1, 2025 | |
| NCT05997277 | Recruiting | Phase 2 | Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). | November 30, 2023 | December 31, 2026 |
| NCT06015438 | Recruiting | N/A | Physical Activity in Hidradenitis Suppurativa (HS) | June 7, 2023 | November 1, 2025 |
| NCT06374212 | Recruiting | Phase 2 | Anifrolumab for Hidradenitis Suppurativa | June 2024 | December 2026 |
| NCT05403710 | Recruiting | Botulinum Toxin Therapy in Hidradenitis Suppurativa | June 7, 2022 | April 30, 2028 | |
| NCT05921994 | Recruiting | Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | August 10, 2023 | December 22, 2026 | |
| NCT05477225 | Recruiting | Phase 4 | A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions | October 1, 2022 | July 30, 2025 |
| NCT04246372 | Recruiting | Phase 2 | Tofacitinib for Immune Skin Conditions in Down Syndrome | October 21, 2020 | December 2024 |
| NCT05507125 | Recruiting | Regulation of Inflammatory Genes in Hidradenitis Suppurativa | October 11, 2022 | August 31, 2026 | |
| NCT03661866 | Recruiting | A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC | December 21, 2018 | December 2050 | |
| NCT05913817 | Recruiting | The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications. | January 9, 2023 | November 13, 2024 | |
| NCT05635266 | Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | October 26, 2021 | October 2025 | |
| NCT06411379 | Recruiting | Phase 3 | Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | May 14, 2024 | June 17, 2026 |
| NCT03827798 | Recruiting | Phase 2 | Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa | February 27, 2019 | October 23, 2026 |
| NCT05642039 | Recruiting | N/A | Mindfulness Training Hidradenitis Suppurativa (HS) | May 1, 2023 | August 31, 2024 |
| NCT05989945 | Recruiting | HIDRAdenitis Suppurativa and HEART Disease | August 1, 2023 | August 1, 2033 | |
| NCT06411899 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | May 15, 2024 | June 17, 2026 |
| NCT05710393 | Recruiting | Hidradenitis - an Analysis of Genetic Traits and Linkages in Families | September 17, 2019 | December 2026 | |
| NCT04218422 | Recruiting | N/A | Battlefield Acupuncture for Pain in Hidradenitis Suppurativa | January 22, 2020 | February 20, 2031 |
| NCT03967600 | Recruiting | Clinical and Biological Characteristics of Hidradenitis Suppurativa | July 15, 2016 | July 15, 2026 | |
| NCT05819398 | Recruiting | Phase 2/Phase 3 | Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa | April 10, 2023 | August 29, 2028 |
| NCT06028230 | Recruiting | Phase 2 | A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | September 29, 2023 | March 14, 2025 |
| NCT06046729 | Recruiting | Phase 2 | A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | October 23, 2023 | July 2026 |
| NCT03146676 | Recruiting | The Ohio State University Dermatology Biorepository | April 19, 2017 | December 31, 2030 | |
| NCT05889182 | Recruiting | Phase 3 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | June 21, 2023 | August 1, 2027 |
| NCT04115566 | Recruiting | Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository | August 1, 2020 | September 1, 2029 | |
| NCT06058520 | Recruiting | Early Phase 1 | Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa | October 1, 2023 | January 1, 2025 |
| NCT05934825 | Recruiting | Phase 1/Phase 2 | Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa | October 26, 2022 | October 26, 2025 |
| NCT06072287 | Recruiting | The Living With a Long-Term Condition Study | June 28, 2023 | January 10, 2024 | |
| NCT05986825 | Recruiting | Validation of the French Version of the Score on Quality of Life (HiSQOL) in Hidradenitis Suppurativa (QUALIVER) | August 29, 2023 | September 2024 | |
| NCT06123429 | Recruiting | N/A | Mindfulness in Hidradenitis Suppurativa | October 3, 2023 | April 1, 2024 |
| NCT04508374 | Recruiting | N/A | Intralesional Diode Laser Treatment of Fistulas in Hidradenitis Suppurativa | December 10, 2020 | September 2025 |
| NCT05020730 | Recruiting | Phase 2 | Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa | May 5, 2022 | June 2024 |
| NCT00367328 | Terminated | Phase 3 | To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa | April 2005 | April 2006 |
| NCT04582669 | Terminated | Phase 4 | Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa | January 24, 2022 | October 12, 2022 |
| NCT03040804 | Terminated | N/A | Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa | March 1, 2017 | December 21, 2020 |
| NCT04988308 | Terminated | Phase 2 | A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa | October 12, 2021 | November 23, 2022 |
| NCT01838499 | Terminated | Phase 2 | Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa | May 2013 | October 2014 |
| NCT03238469 | Terminated | N/A | Microwave Ablation in Mild Axillary Hidradenitis Suppurativa | September 1, 2017 | April 1, 2018 |
| NCT05348681 | Terminated | Phase 2 | A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) | July 18, 2022 | February 28, 2023 |
| NCT05830149 | Terminated | N/A | Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa | February 20, 2018 | April 18, 2018 |
| NCT00722800 | Terminated | Phase 2 | A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS | October 2008 | December 2011 |
| NCT03198390 | Terminated | Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions | August 4, 2017 | May 31, 2020 | |
| NCT04230291 | Terminated | N/A | Hidradenitis Suppurativa Written Action Plan | February 1, 2020 | March 17, 2020 |
| NCT04325607 | Terminated | N/A | Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa | September 1, 2019 | October 1, 2023 |
| NCT03553888 | Unknown status | Hidradenitis Suppurativa and Periodontal Diseases | May 7, 2018 | May 7, 2020 | |
| NCT04792957 | Unknown status | JAK-STAT Signaling Pathway in Pyoderma Gangrenosum | May 1, 2022 | July 31, 2022 | |
| NCT03221621 | Unknown status | Phase 4 | Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS | July 31, 2018 | July 31, 2022 |
| NCT03910803 | Unknown status | Phase 2 | Treatment of Moderate Hidradenitis Suppurativa | May 1, 2019 | May 1, 2020 |
| NCT05531747 | Unknown status | N/A | Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa | September 30, 2022 | March 30, 2024 |
| NCT03203122 | Unknown status | N/A | Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa | August 7, 2017 | August 1, 2019 |
| NCT04982432 | Unknown status | Phase 2 | Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa | October 1, 2021 | December 1, 2022 |
| NCT04073082 | Unknown status | Safety and Efficacy of Laser Therapy in Gynaecology | July 24, 2019 | January 24, 2020 | |
| NCT04249713 | Withdrawn | Early Phase 1 | An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab | February 3, 2020 | September 2020 |
| NCT03929835 | Withdrawn | Phase 2 | Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa | September 1, 2020 | September 1, 2022 |
| NCT04084665 | Withdrawn | Early Phase 1 | Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. | June 1, 2020 | July 30, 2020 |
| NCT04541550 | Withdrawn | Phase 1 | Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa | April 1, 2021 | July 1, 2021 |
| NCT05255575 | Withdrawn | A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa | March 1, 2018 | August 7, 2019 | |
| NCT04100083 | Withdrawn | Phase 4 | Spironolactone for Hidradenitis Suppurativa | September 21, 2020 | June 21, 2021 |
| NCT04132388 | Withdrawn | Phase 4 | Hidradenitis Suppurativa Patient Experience With Humira Treatment | August 20, 2020 | September 7, 2022 |
- Exact Synonym (Disease Ontology)
- Acne inversa, familial
- Disase is a (Disease Ontology)
- DOID:2282
- Cross Reference ID (Disease Ontology)
- GARD:6658
- Cross Reference ID (Disease Ontology)
- ICD10CM:L73.2
- Cross Reference ID (Disease Ontology)
- MESH:D017497
- Cross Reference ID (Disease Ontology)
- MIM:142690
- Cross Reference ID (Disease Ontology)
- MIM:613736
- Cross Reference ID (Disease Ontology)
- MIM:613737
- Cross Reference ID (Disease Ontology)
- NCI:C128429
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:201204008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0162836
- ICD10 class code (Insert disease from ICD10)
- L73.2
- ICD10 preferred id (Insert disease from ICD10)
- D0009917
- MeSH unique ID (MeSH (Medical Subject Headings))
- D017497